IM Cannabis (NASDAQ:IMCC – Get Free Report) and MediciNova (NASDAQ:MNOV – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.
Volatility & Risk
IM Cannabis has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
Insider and Institutional Ownership
7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 5.9% of IM Cannabis shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
| MediciNova | 1 | 1 | 3 | 1 | 2.67 |
MediciNova has a consensus target price of $8.33, indicating a potential upside of 414.40%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than IM Cannabis.
Profitability
This table compares IM Cannabis and MediciNova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
| MediciNova | -1,168.70% | -26.51% | -24.39% |
Earnings and Valuation
This table compares IM Cannabis and MediciNova”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($2.02) | -1.09 |
| MediciNova | $410,000.00 | 194.48 | -$12.00 million | ($0.21) | -7.71 |
IM Cannabis has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
Summary
MediciNova beats IM Cannabis on 10 of the 15 factors compared between the two stocks.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
About MediciNova
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
